Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Active surveillance (AS) and radical prostatectomy (RP) are both accepted treatments for men with favorable-risk localized prostate cancer (PCa) (ie, clinical tumor category 1-2b, Gleason Grade Group 1-2, and prostate-specific antigen < 20 ng/mL). However, head-to-head studies comparing oncologic outcomes and survival between these 2 treatment strategies are warranted. The objective of this study was to compare the use of prostate cancer treatments and PCa death in men managed on AS and men who underwent immediate RP.

PATIENTS AND METHODS: This was an observational study including 647 men on AS and 647 men treated with RP propensity score matched. We examined the 10-year cumulative incidence of salvage radiotherapy, hormonal therapy, castration-resistant PCa, and PCa death.

RESULTS: The 10-year curative treatment-free survival for men on AS was 61% (95% confidence interval [CI], 57%-65%). No differences in use of salvage radiotherapy (AS, 2.7%; 95% CI, 1.4%-4.1% vs. RP 5.4%; 95% CI, 3.4%-7.3%), hormonal therapy (AS, 6.9%; 95% CI, 4.4%-9.4% vs. RP, 4.1%; 95% CI, 2.5%-5.6%), developing castration-resistant PCa (AS, 1.7%; 95% CI, 0.5%-2.9% vs. RP, 2.0%; 95% CI, 0.7%-3.4%), or cumulative PCa mortality (AS, 0.4%; 95% CI, 0%-1.0% vs. RP, 0.5%; 95% CI, 0%-1.5%) were observed between the treatment strategies. The main limitation was the non-random allocation to treatment strategy.

CONCLUSION: In this observational study on men with favorable-risk localized PCa, we found similar PCa mortality at 10 years between men on AS and men who underwent immediate RP. Moreover, there were no differences in the use of PCa therapies between the groups. Our study supports active surveillance as a treatment strategy for men with favorable-risk localized PCa.

Original languageEnglish
JournalClinical Genitourinary Cancer
ISSN1938-0682
DOIs
Publication statusE-pub ahead of print - 21 May 2019

ID: 57420011